TherapeuticsMD, Inc. (OTCQB: TXMD) today announced that it intends to
offer and sell, subject to market and other conditions, $50,000,000 of
its common stock in an underwritten public offering. There can be no
assurance as to whether or when the offering may be completed, or as to
the actual size or terms of the offering.
Jefferies LLC is acting as sole book-running manager for the offering,
and Noble Financial Capital Markets is acting as co-manager for the
offering.
A shelf registration statement relating to the public offering of the
shares of common stock described above was filed with the Securities and
Exchange Commission (SEC) and is effective. A preliminary prospectus
supplement related to the offering will be filed with the SEC and will
be available on the SEC’s website located at www.sec.gov.
Copies of the preliminary prospectus supplement and the accompanying
prospectus relating to this offering, when available, may be obtained
from Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, 12th Floor, New York, NY 10022, by telephone at
(877) 547-6340, or by e-mail at Prospectus_Department@Jefferies.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor will there be any
sale of these securities in any state or other jurisdiction in which
such offer, solicitation, or sale is not permitted. Any offer, if at
all, will be made only by means of a prospectus, including a prospectus
supplement, forming part of the effective shelf registration statement.
About TherapeuticsMD
TherapeuticsMD, Inc. is a women’s healthcare product company focused on
creating and commercializing products targeted exclusively for women.
The Company currently manufactures and distributes branded and generic
prescription prenatal vitamins as well as over-the-counter vitamins and
cosmetics. The Company is currently focused on conducting the clinical
trials necessary for regulatory approval and commercialization of
advanced hormone therapy pharmaceutical products designed to alleviate
the symptoms of and reduce the health risks resulting from
menopause-related hormone deficiencies.
Forward-Looking Statements
Except for the historical information contained herein, the matters
set forth in this press release, including statements regarding
TherapeuticsMD’s expectations with respect to the completion, timing and
size of its proposed offering, are forward-looking statements within the
meaning of the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
subject to risks and uncertainties that may cause actual results to
differ materially, including the risks and uncertainties associated with
market conditions, the satisfaction of customary closing conditions
related to the proposed offering, risks and uncertainties associated
with TherapeuticsMD’s business and finances in general, and other risks
detailed in TherapeuticsMD’s annual report on Form 10-K filed with the
SEC on March 27, 2012, current report on Form 8-K filed with the SEC on
January 25, 2013, and other filings with the SEC. These forward-looking
statements are based on current information that may change and you are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release. All
forward-looking statements are qualified in their entirety by this
cautionary statement, and TherapeuticsMD undertakes no obligation to
revise or update any forward-looking statement to reflect events or
circumstances after the issuance of this press release.
